Welcome to our book review site go-pdf.online!
You may have to Search all our reviewed books and magazines, click the sign up button below to create a free account.
Fast Facts: EGFR Exon 20 Insertion Mutations in NSCLC
Lung cancer is still a major cause of death globally, but the development of personalized, precision medicine has had a marked effect on treatment management and improved clinical outcomes, particularly for those with advanced stage non-small-cell lung cancer (NSCLC). EGFR mutations are the third most common mutation found in patients with advanced stage NSCLC. First-line treatment with a traditional epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) is indicated for most patients, but not for patients with EGFR exon 20 insertion mutations (ex20ins). Instead, recent approvals of an EGFR ex20ins-specific TKI (mobocertinib) and a bispecific antibody (amivantamab) targeting both EGFR and mesenchymalepithelial transition factor (MET) offer the potential for improved outcomes in this patient population. Furthermore, new approaches to treatment continue to be developed and trials for new agents with greater activity against ex20ins mutations are ongoing. Table of Contents: • EGFR and mutations • EGFR mutation testing • Treatment decisions • Therapies in development
Lung Cancer, An Issue of Hematology/Oncology Clinics of North America, E-Book
In this issue of Hematology/Oncology Clinics, guest editors Drs. Sarah B. Goldberg and Roy S. Herbst bring their considerable expertise to the topic of Lung Cancer. Top experts in the field cover key topics such as state-of-the-art pathologic and molecular testing; neoadjuvant vs. adjuvant therapy for early-stage NSCLC; new therapies on the horizon (immunotherapy, ADCs, etc.); supportive care and symptom management; smoking cessation; and more. - Contains 15 relevant, practice-oriented topics including lung cancer screening; advances in surgical techniques for lung cancer; non-surgical therapy for early-stage lung cancer; locally advanced lung cancer; what's new in small cell lung cancer; and more. - Provides in-depth clinical reviews on lung cancer, offering actionable insights for clinical practice. - Presents the latest information on this timely, focused topic under the leadership of experienced editors in the field. Authors synthesize and distill the latest research and practice guidelines to create clinically significant, topic-based reviews.
Advances in the use of EGFR TKIs in the Treatment of NSCLC
Lung cancer is the leading cause of cancer-related deaths worldwide. Non-small cell lung cancer (NSCLC) is the most common type of lung cancer, accounting for approximately 85% of all cases. Over the last decade, there have been significant advances in the treatment of NSCLC, particularly with the use of epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs). EGFR is a key driver of NSCLC, and EGFR TKIs have shown remarkable clinical activity in patients with EGFR-mutant NSCLC. Despite these advances, however, there are still many unanswered questions regarding the optimal use of EGFR TKIs in the treatment of NSCLC. To improve patient outcomes, further research into the use of EGFR TKIs in lung cancer therapy is vital. Our goal is to provide an overview of the latest advances in the use of EGFR TKIs in the treatment of NSCLC.
AACR 2019 Proceedings: Abstracts 2749-5314
American Association for Cancer Research 2019 Proceedings: Abstracts 2749-5314 - Part B
AACR 2022 Proceedings: Part B April 11-13
The AACR Annual Meeting is the focal point of the cancer research community, where scientists, clinicians, other health care professionals, survivors, patients, and advocates gather to share the latest advances in cancer science and medicine. From population science and prevention; to cancer biology, translational, and clinical studies; to survivorship and advocacy; the AACR Annual Meeting highlights the work of the best minds in cancer research from institutions all over the world.
Oncology Rapid Review Flash Cards
Face the oncology board exam with confidence! Oncology Rapid Review, created and edited by Drs. Utkarsh H. Acharya and Tejaswini Dhawale, is a conveniently portable, effective review tool that helps you prepare for this comprehensive and challenging exam. Sturdy, full-color flash cards provide a focused, case-based review anytime, anywhere.
Donnstags-Blatt
None
Clinical Radiation Oncology E-Book
Perfect for radiation oncology physicians and residents needing a multidisciplinary, treatment-focused resource, this updated edition continues to provide the latest knowledge in this consistently growing field. Not only will you broaden your understanding of the basic biology of disease processes, you'll also access updated treatment algorithms, information on techniques, and state-of-the-art modalities. The consistent and concise format provides just the right amount of information, making Clinical Radiation Oncology a welcome resource for use by the entire radiation oncology team. Content is templated and divided into three sections -- Scientific Foundations of Radiation Oncology, Techniq...
Hematology Rapid Review
Face the hematology board certification with confidence! Hematology Rapid Review, created and edited by Drs. Utkarsh H. Acharya and Tejaswini Dhawale, is a conveniently portable and effective review tool that helps learners at all levels prepare for this challenging exam. Sturdy, full-colored, flash cards provide an efficient and focused review anytime, anywhere.
